11-顺式-3-羟基视黄醛 | 102918-00-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 11-顺式-3-羟基视黄醛
• 英文名称: all trans, 11-cis 3-hydroxyretinal
• 英文别名: 11-cis-3-Hydroxyretinal；(2E,4Z,6E,8E)-9-(4-hydroxy-2,6,6-trimethylcyclohexen-1-yl)-3,7-dimethylnona-2,4,6,8-tetraenal
• CAS: 102918-00-3
• 化学式: C₂₀H₂₈O₂
• 分子量: 300.441
• InChiKey: QPRQNCDEPWLQRO-SKVGZCNQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  11-顺式-3-羟基视黄醛 生成 all trans, 13-cis 3-hydroxyretinal
  参考文献：
  名称：

  ITO, MASAYOSHI;MATSUOKA, NOZOMI;TSUKIDA, KIYOSHI;SEKI, TAKAHARU, CHEM. AND PHARM. BULL., 36,(1988) N 1, 78-86

  摘要：

  DOI：
• 作为产物：
  描述：

  methyl (2E,4E,6E,8E)-9-(4-hydroxy-2,6,6-trimethylcyclohexen-1-yl)-3,7-dimethylnona-2,4,6,8-tetraenoate 生成 11-顺式-3-羟基视黄醛
  参考文献：
  名称：

  ITO, MASAYOSHI;MATSUOKA, NOZOMI;TSUKIDA, KIYOSHI;SEKI, TAKAHARU, CHEM. AND PHARM. BULL., 36,(1988) N 1, 78-86

  摘要：

  DOI：

文献信息

• Retinoids and related compounds. X. Synthesis of geometrical isomers of (.+-.)-2- and (.+-.)-3-Hydroxyretinals and identification of the cromophore of the fly visual pigment.
  作者：MASAYOSHI ITO、NOZOMI MATSUOKA、KIYOSHI TSUKIDA、TAKAHARU SEKI

  DOI：10.1248/cpb.36.78

  日期：——

  The geometrical isomers of (±)-3-hydroxyretinals were synthesized and characterized. Subsequently, simultaneous separation of eight isomers of 2- and 3-hydroxyretinals by high-performance liquid chromatography (HPLC) was accomplished and, in addition, complete separation of eight syn-anti isomers of 3-hydroxyretinaloximes by HPLC was achieved. Under these analytical conditions, the chromophore of the fly (Drosphila melanogaster) visual pigment was identified as 11-cis-3-hydroxyretinal (10).

  合成了（±）-3-羟基视黄醛的几何异构体并对其进行了表征。随后，通过高效液相色谱（HPLC）同时分离了8种2-和3-羟基视黄醛的异构体，并且实现了8种顺-反异构体3-羟基视黄醛肟的完全分离。在这些分析条件下，果蝇（黑腹果蝇）视色素的发色团被鉴定为11-顺式-3-羟基视黄醛（10）。
• DRUG DELIVERY IMPLANTS AS INTRAOCULAR DRUG DEPOTS AND METHODS OF USING SAME
  申请人：DOSE MEDICAL CORPORATION

  公开号：US20180333296A1

  公开（公告）日：2018-11-22

  Disclosed herein are drug delivery implants configured to be implanted into the eye of a subject and serve as intraocular drug depots. The implants reside in an intraocular target site until activation, at which time the implants release the drug (or drugs) housed within the implant in a controlled release fashion.